ZIM Laboratories Limited develops, manufactures, and supplies generic pharmaceutical and nutraceutical products in India and internationally. The company provides its products in pre- formulation intermediates and finished formulations using modified release patterns in the oral solid dosage forms, such as granules, pellets, taste-masked powders, suspensions, tablets, capsules, dry syrup, and oral thin films. It offers therapeutics in the areas of urology, gastroenterology, CNS, antibiotics, anti-infectives, NSAIDs/pain analgesics, and vitamins and supplements. ZIM Laboratories Limited was incorporated in 1984 and is based in Nagpur, India.

ZIM Laboratories Limited

ZIM Labs develops, manufactures, and supplies differentiated generic products in oral solid dosage forms, including pre-formulation intermediates and finished formulations. They also offer pharmaceutical and nutraceutical products. The company is self-described as research-driven and focuses on innovative process technologies for patient compliance.

	Mar '21	Jun '21	Dec '21	Mar '22	Jun '22	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23
net income	15.50M -	1.89M 87.82%	40.73M 2,058.29%	70.30M 72.62%	51.48M 26.78%	54.50M 5.86%	66.01M 21.12%	72.36M 9.63%	2.27M 96.87%	41.49M 1,731.20%	47.85M 15.31%
depreciation and amortization						43.72M -	38.97M 10.85%	49.30M 26.50%	40.26M 18.35%	40.85M 1.49%	39.35M 3.67%
deferred income tax
stock based compensation
change in working capital
accounts receivables
inventory
accounts payables
other working capital
other non cash items	-15.50M -	-1.89M 87.82%	-40.73M 2,058.29%	-70.30M 72.62%	-51.48M 26.78%	-43.72M 15.08%	-38.97M 10.85%	-49.30M 26.50%	-40.26M 18.35%	-40.85M 1.49%	-39.35M 3.67%
net cash provided by operating activities	15.50M -	1.89M 87.82%	40.73M 2,058.29%	70.30M 72.62%	51.48M 26.78%	54.50M 5.86%	66.01M 21.12%	72.36M 9.63%	2.27M 96.87%	41.49M 1,731.20%	47.85M 15.31%
investments in property plant and equipment
acquisitions net
purchases of investments
sales maturities of investments
other investing activites
net cash used for investing activites
debt repayment
common stock issued
common stock repurchased
dividends paid
other financing activites
net cash used provided by financing activities
effect of forex changes on cash
net change in cash	15.50M -	1.89M 87.82%	40.73M 2,058.29%	70.30M 72.62%	51.48M 26.78%	54.50M 5.86%	-23.83M 143.72%	72.36M 403.72%	-63.92M 188.34%	41.49M 164.91%	-123.83M 398.43%
cash at beginning of period						35.34M -	89.83M 154.23%	-6.17M 106.87%	66.19M 1,172.08%	130.18M 96.68%	171.68M 31.87%
cash at end of period	15.50M -	1.89M 87.82%	40.73M 2,058.29%	70.30M 72.62%	51.48M 26.78%	89.83M 74.51%	66.01M 26.52%	66.19M 0.28%	2.27M 96.58%	171.68M 7,476.26%	47.85M 72.13%
operating cash flow	15.50M -	1.89M 87.82%	40.73M 2,058.29%	70.30M 72.62%	51.48M 26.78%	54.50M 5.86%	66.01M 21.12%	72.36M 9.63%	2.27M 96.87%	41.49M 1,731.20%	47.85M 15.31%
capital expenditure
free cash flow	15.50M -	1.89M 87.82%	40.73M 2,058.29%	70.30M 72.62%	51.48M 26.78%	54.50M 5.86%	66.01M 21.12%	72.36M 9.63%	2.27M 96.87%	41.49M 1,731.20%	47.85M 15.31%

IN:ZIMLAB

ZIM Labs

Last Close

103.35

22/11 09:59

Market Cap

5.36B

Beta: -

Volume Today

18.85K

Avg: -

Preview